Canaccord analyst Whitney Ijem raised the firm’s price target on Passage Bio to $14 from $8 and keeps a Buy rating on the shares. The firm said the company’s FTD data release is off to a good start, and they can appreciate the company’s need to carefully allocate capital towards high value programs.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on PASG:
- Passage Bio announces anticipated upcoming milestones
- Passage Bio to explore therapeutic potential of PBFT02 in multiple diseases
- Passage Bio Announces Promising Initial Data From Phase 1/2 Clinical Trial of PBFT02 in FTD-GRN and Updated Strategic Priorities
- Passage Bio announces initial data from Phase 1/2 trial of PBFT02
- Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
